Evidence map›Paper›PMID 37020941›Full record

ArticleHeliyon2023

Nebulization of pharmacological solutions with an innovative medical device based on microvaporization.

Bruno Brandimarte, Lino Di Rienzo Businco, Francesco Cappello, Roberto Fiore, Giuseppe Bastone, Gianfranco Gualdi, Saadi Sollaku, Emanuele Casciani, Federica Tortorella, Pasquale Longo and 8 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Heliyon, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.5field-weighted citation impact, top 31% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 2 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors at 8 institutions in 3 countries.

Bruno BrandimarteElectronic Measurements Physics Department, Sapienza University, Rome, Italy.
Lino Di Rienzo BusincoOtorhinolaryngology Department, Institute of Sport Medicine, Sport e Salute, Rome, Italy.
Francesco CappelloDepartment of Biomedicine, Neuroscience and Advanced Diagnostics, University of Palermo, and Euro-Mediterranean Institute of Science and Technology, Palermo, Italy.
Roberto FioreSport Medicine Department, Institute of Sport Medicine, Sport e Salute, Rome, Italy.
Giuseppe BastoneSport Medicine Department, Institute of Sport Medicine, Sport e Salute, Rome, Italy.
Gianfranco GualdiRadiology Department, Casa di Cura Pio XI and Sapienza University, Rome, Italy.
Saadi SollakuNuclear Medicine, Casa di Cura Pio XI, Rome, Italy.
Emanuele CascianiNuclear Medicine, Casa di Cura Pio XI, Rome, Italy.
Federica TortorellaOtorhinolaryngology Department, Institute of Sport Medicine, Sport e Salute, Rome, Italy.
Pasquale LongoOtorhinolaryngology Department, Institute of Sport Medicine, Sport e Salute, Rome, Italy.
Eleonora CentaniniDepartment of Pharmacy, Health and Nutritional Sciences, University of Calabria, Rende, Italy.
Silva PavaciOtorhinolaryngology Department, Institute of Sport Medicine, Sport e Salute, Rome, Italy.
Federica SangiuoloDepartment of Biomedicine and Prevention, Tor Vergata University of Rome, Rome, Italy.
Maria Patrizia PatriziFondazione Livio Patrizi, Rome, Italy.
Shane MierschDepartment of Molecular Genetics, The Donnelly Centre, University of Toronto, Toronto, Ontario, Canada.
Sachdev S SidhuDepartment of Molecular Genetics, The Donnelly Centre, University of Toronto, Toronto, Ontario, Canada.
Virgilio SacchiniBreast Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, USA.
Giuseppe NovelliDepartment of Biomedicine and Prevention, Tor Vergata University of Rome, Rome, Italy.
Federazione Medico Sportiva Italiana · ITUniversity of Rome Tor Vergata · ITUniversity of Toronto · CAFondazione Roma · ITMemorial Sloan Kettering Cancer Center · USSapienza University of Rome · ITUniversity of Calabria · ITUniversity of Palermo · IT

Funding

X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI FRANCESCA M GANY · 1985 to 2026
$347.4M
NCI NIH HHS P30 CA008748
6 · The paper itself

Abstract

The currently available nebulization devices have a slow aerosol flow and produce vapor with large microdrops. Improved devices that achieve higher airflow and produce smaller microdrops are needed to improve the clinical care of patients. To address this critical need, we developed a novel system for the molecular vaporization of liquids. This device vaporizes an active pharmacological substance dissolved in water, alcohol, or a mixture of water and alcohol using two energy sources at the same time: high-frequency ultrasound and thermal induction. Application of energy to a solution contained in the device's tank allows, within tens of seconds, for the vaporization of the solution itself, with the generation of a vapor consisting of microdrops of very small diameter (0.2-0.3 μm). In this article, we illustrate the technology used, the main verification tests performed, and the primary fields of application for this device. In particular, the advantages of both the aerosol delivery system and the administration system are highlighted.

Indexed as

AerosolCOVID-19Drug delivery deviceInduction energyMicrodrop

Identifiers

PMID37020941
PMCPMC10068108
OpenAlexW4327923964

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.